Kazakhstan Pharmaceutical & Healthcare Industries Overview 2017 and Forecast for 2017-2019

13:42

REPORT SUMMARY

The Overview uncovers economic, pharmaceutical and healthcare insights in a tailored made systematic and business styled manner.


Report name:Pharmaceutical and Healthcare Industries Overview 2017
Country:Kazakhstan
Data years:2011-1HY 2017
Forecast for:2017-2019
Price:EUR 500
Contents:Download contents
How to buy:


This report is intended for decision makers, industry professionals, and other stakeholders globally.

The report covers a 2016 full year data with the forecast of the economics and pharmaceutical market growth to 2017-2019.


KAZAKH ECONOMY SUMMARY

This article is based on the Kazakhstan Pharmaceutical and Healthcare Industries Overview 2017 developed by UPharma Consulting. The full report is available for purchase.

The Republic of Kazakhstan is an upper-middle-income country (according to the World Bank’s classification) located predominately in Central Asia. Kazakhstan is the world’s largest landlocked country and the 9th largest country in the world by land area. At the same time, Kazakhstan is the 227th country in the world by population density.

Kazakhstan’s economy is the largest one in Central Asia while about half of the country’s GDP is contributed by industries based on raw materials. According to British Petroleum's estimates, Kazakhstan possesses 3.2% of the world’s oil reserves and 1.7% of the world’s gas reserves.
After in 2006 the Kazakhstan’s GDP had grown significantly by (10.6%) in a virtue of boost of trade relations with Russia, China, and the CIS countries, in 2008 the economy was affected by the global financial crisis.n 2014, due to the consequences of the Ukrainian crisis and oil prices fall, the GDP growth in Kazakhstan slowed down, while the country’s currency devalued by 19% in February 2014.

Kazakhstan’s economy continued to suffer from a protracted slowdown in global oil prices and weak domestic demand. Real GDP growth declined from 1.2% in 2015 to an estimated 1% in 2016.
The economic slowdown negatively affected the labour market and affected household income adversely in 2016, with the decline in average real wages (0.9%) and employment (0.5%).

According to the latest EBRD Transition Report, after struggling with poor growth and social unrest in 2016 due to low commodity prices, the World Bank expects the Kazakh economy to rebound in 2017. Large uncertainties remain around the two parallel reforms.

One the one hand, the language of the announcement on political reform was vague and heavily wrapped in rhetoric.

PHARMACEUTICAL MARKET OF KAZAKHSTAN

Pharmaceutical market of Kazakhstan is the biggest and the most structured one in Central Asia. However, it is weaker compared to the CEE market in terms of business environment and its amount.

Kazakhstan pharmaceutical market started its formation in the middle 1990s. In 1994, the provision of drugs in the country was carried by the State Joint Stock Holding “Pharmacia” owning 1832 pharmacies. After the demonopolization of the Holding and privatization of its pharmacies, the national drug provision system was destroyed.

In 1996, transformation processes allowed developing a drugs provision system based on market relationships.

Currently, the pharmaceutical market of Kazakhstan is among the most developed ones in the CIS region. Consolidation and evolution of vertically integrated companies can be seen in local producers, distributors, and pharmacies together with the improvement of service culture.

Despite considerable growth dynamics (the market rose 14.3% in 2010-2014), the contribution of the pharmaceutical industry in the country’s GDP remains quite low – 0.2% in values in 2016. The main reason for this is a relatively low base of the local pharmaceutical industry.

Big expectations are related to the formation of a common market of drugs and medical devices within the EEU. Kazakh producers plan to enhance the export of pharmaceuticals to the EEU states to USD 360 mio per year. The common market foresees harmonization of rules for drugs circulation and registration as well as quality standards for drugs...

The full version of the report is available for purchase now.

Other reports

Source: UPharma Consulting

Leave a Comment

Powered by Blogger.